Company
Anika Therapeutics
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
15
As lead sponsor, any status
Adverse event reports
28
Received Nov 1, 2025 to Nov 20, 2026
Recall records
13
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
ANIK
Nasdaq · Anika Therapeutics, Inc.
Public float
$147M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$113M
Fiscal year ending Dec 31, 2025
Net income
-$10.9M
Fiscal year ending Dec 31, 2025
R&D spending
$25.8M
Fiscal year ending Dec 31, 2025
Cash
$45.0M
As of Sep 30, 2026
Long-term debt
Not reported
Shares outstanding
13.4M
As of Oct 30, 2026
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
The investor database is free with an account
Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.
Latest FDA decisions
The 8 newest of 11 since 2015.
K261869 · Decided Sep 17, 2026 · 105 days after receipt
Device type: Fastener, Fixation, Nondegradable, Soft Tissue (MBI) · Orthopedic Surgery
10 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06741527 · 150 participants (planned) · Start Feb 1, 2025 · Primary completion Jun 2027
Device: Integrity Implant System · For: Rotator Cuff Tears of the Shoulder
Sites: Gilbert, Arizona; Pomona, California; Tampa, Florida · 9 sites in all
14 more trials with a free account
Reports received
28
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
3
11% of reports
Injury reports
25
89% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 1 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 1 | 0 |
| Apr 24 | 0 | 0 | 0 | 1 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 5 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 1 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 1 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 1 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 2 | 0 | 0 |
| Jul 25 | 0 | 0 | 1 | 0 |
| Aug 25 | 0 | 3 | 0 | 0 |
| Sep 25 | 0 | 1 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 3 | 0 | 0 | 0 |
| Jan 26 | 0 | 2 | 0 | 0 |
| Feb 26 | 0 | 3 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 2 | 0 | 0 |
| Jul 26 | 0 | 5 | 0 | 0 |
| Aug 26 | 0 | 6 | 0 | 0 |
| Sep 26 | 0 | 6 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
The full in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- Monovisc16
1 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2423-2018 · Started May 10, 2018
Reason given: Hyalomatrix products are susceptible to degradation as a result of the decomposition of PVC in the packaging material during sterilization, which resulted in degradation of the film. Over the long term it is possible that product integrity may be compromised.
Cause as FDA categorized it: Package design/selection · Device type: Dressing, Wound, Drug (FRO)
12 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.